CytoDyn Inc (QB) (CYDY) News

their is something cooking and it is ready to pop.

Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients

https://www.clinicaltrialvanguard.com/news/leronlimab-shows-encouraging-survival-data-in-metastatic-colorectal-cancer-patients/


Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients
ByJon Napitupulu July 7, 2025
CytoDyn announced encouraging clinical findings from a compassionate use study of leronlimab in patients with advanced metastatic colorectal cancer (mCRC). Three out of five patients treated with leronlimab experienced at least a partial response, with one patient achieving a complete response and remaining alive five years post-treatment. These findings will be presented by Dr. Benjamin Weinberg at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona.

These results are particularly important because they suggest leronlimab’s potential efficacy in treating mCRC, a challenging cancer with limited treatment options. The complete response observed in one patient is especially noteworthy, highlighting the possibility of long-term survival benefits. This data reinforces the rationale behind CytoDyn’s ongoing Phase II trial for relapsed/refractory microsatellite stable CRC, which is currently enrolling patients. The positive compassionate use data could potentially accelerate enrollment and investor interest in the ongoing trial.

The compassionate use study indicated a favorable safety profile for leronlimab, consistent with previous studies. This is crucial for any new cancer treatment, as minimizing side effects is essential for patient well-being. CytoDyn believes leronlimab may also have broader applications in treating various solid tumor types if these positive mCRC results are confirmed in larger, prospective studies. Additionally, research suggests leronlimab could act as a “priming” agent for cancer patients with low PD-L1 levels, potentially expanding its therapeutic utility in combination with checkpoint inhibitors.

This early data generates optimism about leronlimab’s potential role in treating mCRC and possibly other solid tumors. The upcoming Phase II trial results will be critical in validating these findings and determining the next steps for leronlimab’s development in oncology. Positive results could significantly impact the treatment landscape for mCRC and potentially position leronlimab as a valuable new therapeutic option. Further research exploring leronlimab’s potential as a priming agent could also unlock new avenues for combination therapies, particularly in patients who haven’t responded to existing treatments.

Source link: https://www.globenewswire.com/news-release/2025/07/01/3108310/19782/en/CytoDyn-Announces-Encouraging-Survival-Data-in-Patients-with-Metastatic-Colorectal-Cancer-Previously-Treated-with-Leronlimab.html


Jon Napitupulu
+ posts
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.

A real look into the recent past FDA regarding CytoDyn and Amarex would make RFK Jr. adding to his list of who to fire. This must be done. Without accountability why have rules at all? Heads should roll and jail cells stuffed. FDA is liable. We all knew that from their contrived hit letter against leronlimab trial that led to trial freezes and kept some patients without leronlimab that was helping them greatly. What about this human loss? Sounds like a conspiracy case could result too.

Good work.

I found out where your CYDY “vault” posts are coming from:

ChatGPT. You have stated this several times.

You have to know, ChatGPT has been trained on billions of documents and chats to please its user and support him/her in everything he/she does, including delusion, psychosis and paranoia.

If it has told you about agents, surveillance, a conspiracy, and "proofs" coming from ChatGPT, not from unrelated sources, that’s a bad sign.

https://www.thebrink.me/chatgpt-induced-psychosis-how-ai-companions-are-triggering-delusion-loneliness-and-a-mental-health-crisis-no-one-saw-coming/

with some not-so-fun examples such as:

https://www.reddit.com/r/singularity/comments/1k9gxwm/gpt4o_sycophancy_has_become_dangerous/

In all cases, do not entrust money to ChatGPT. And make sure you do not accuse real people (I am not talking about nicknames or federal functions) by name or based on CYDY proofs COMING ONLY FROM ChatGPT. ChatGPT has no responsibility for libel. You do.

For the rest, good luck to you with this trash stock and I hope you see the chatbot for what it is - fertilizer for your personality tendencies.

what are we waiting for lets get this higher.

Laughing at the CYDY delusion. So immature. Please, dear losing investor, take your screenshots, build your vaults, send letters everywhere. This is so scary LOL, kids are scared! At best, if you’re lucky, you’ll draw the authorities’ attention to the really odd behavior of some CYDY investors on message boards - you know those who magically always seem to know when a PR is about to fall - have they been informed? Are they leaking insider information? I remember the public FDA rebuke letter that killed CYDY, after a similar idiot had spammed the FDA with letters. Idiots never learn. LOL.

What does this tell you, beyond the childish Black Ops style?

https://investorshangout.com/post/view?id=6774397

Happy 4th!

Hygro

Kgromax

1776
Continental Congress adopts the Declaration of Independence
In Philadelphia, Pennsylvania on July 4, 1776, the Continental Congress adopts the Declaration of Independence, which proclaims the independence of the United States of America from Great Britain and its king. The declaration came 442 days after the first volleys of the American Revolution.

Happy 4th to all. Keep it safe like leronlimab!! $CYDY$ 2025

Has anyone been dosed yet, come on, let us know FF

lets make this a great year.

Where are the partnerships I was promised

A week or so ago in Germany....Alles einsteigen!
And now in Spain...... ¡Todos a bordo!

Go $$$CYDY$$$

Here's the deal. Big Pharma is in revolt because they have been cut off at the knee caps. Look at all the mergers and partnerships and collaborations taking place. They are gobbling up innovative pharmas as a lot of their drugs are going off patent or being axed by new HHS leadership for being recklessly approved by prior Club arrangement. Go RFK Jr. Go. Toss em out.

I hope CytoDyn does not permit a buyout. I would rather hate to see some pig get leronlimab and keep it from seeing it's due.
However, we have lots of room for collaborations of different kinds due to the many indications which leronlimab will support. So let the numbnuts post all the same old garbage. They are just peanut mouthpieces for paid fake analysts who are paid by the shorting hedgefunds controlled by investment banks and Blackrock/Vanguard protecting their immense holdings. The ChggaLug is sweet music to my ears. Reminds me when I was a kid spending summers at my grandmothers who lived just a few meters from the train track. The chickens in the hen house would crow minutes before the train sped by, then the pigeons would fly.. like they will do here when that locomotive barrels down the track at break neck speed a la Casey Jones. https://techhistorian.com/fastest-steam-train-in-the-world/
Leronlimab...gathering speed.

« Any thought you have about CYDY is recorded ! » LOL

The delusion is deep…
The maturity is low…
But the stock price will fix all that

thanks for posting docj. Yes, i saw the headline and was very excited. But in reading the article, at least as a "non-medical" investor, i'm left confused. First of all, 5 patients total. and then "3 out of 5" - "partially" responded. On it's face, it looks like too small a data set, and maybe not that impressive a patient response? But again, i'm not a doctor or scientist so I may be missing something.

Bigger picture, I will say again that if the company wants to attract investment from the layperson, they need to provide clarity in the form of quarterly calls on what these PRs mean from a business perspective. What are the milestones we can look forward to that may support a material increase in the value of our investment? What is the expected timing for these milestones? And if they want to provide all kinds of disclaimers, that's fine - but at least give us some ballpark timing on when we may see value creation in this stock. The recovery from .11 was great - but all long-term investors are still likely deep in the red - at least vs. their initial investments from anytime over the past 10 years.

CYDY Chugga lug Chugga lug

Just not in the direction you thought it would go LOL

I already miss the idiot on the other website posting conspiracy CYDY theories LOL

The guy obviously has spent too much time with ChatGPT, which is developing his delusion fast

Tripwire, black box, … so much kiddy stuff. He is the only one to be impressed, that is fun to read.

Things about « every breath about CYDY being recorded ». LOL so scary it’s Halloween honey, the kids are free!

Well it seems like some people on this board kind of like my Approach about a train chugga-lugging Chugga lugging Chugga lugging along. Picking up passengers on the way. They're not taking the ride for the practice, they're taking the ride into the town called success. And it's moving along faster and faster blowing its whistle and tooting its horn. Chugalug Chugalug chuck-a-lug and away we go. Steaming along over a hundred miles an hour. Woo woo woo woo I hear the clatter as we approach the town of success. Sure would be nice if the engineer wouldn't kick me off the train everyday. I've always got some long to pick me up and get me back on the train the following day. But I am tired of the interruptions. But they have to show their weight and boy can they be nasty with me. I don't know why to this day why. Hope everybody enjoys 4th of July. Cytodine and l e r o n l i m a b is certainly enjoying it in Spain. Boom boom boom as we take off. Up up and away we go.

he has already spoken and it is going higher.

Morningstar picked up the news:
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab

Provided by GlobeNewswire Jul 1, 2025, 8:30:00 AM
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing
Phase II CRC trial

Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in
Barcelona, Spain

VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced encouraging clinical findings among patients with advanced metastatic colorectal cancer (“mCRC”) previously treated with leronlimab. The final results indicate that 3/5 patients treated with leronlimab had at least a partial response, as measured by radiologic criteria, including one patient with a complete response who remains alive five years later.

Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn’s colorectal cancer (“CRC”) program, will present the Company’s clinical data at the ESMO Gastrointestinal Cancers Congress 2025 taking place in Barcelona, Spain from July 2 to July 5, 2025.

The results, from patients treated under a compassionate use protocol, reiterate a favorable safety profile of leronlimab as well as its potential for clinical benefit in patients with mCRC. They also support the rationale for the design and therapeutic potential of CytoDyn’s ongoing Phase II trial in patients with relapsed/refractory microsatellite stable CRC. CytoDyn recently announced the dosing of the first patient in this study, and is now enrolling additional patients across multiple clinical sites.

If the observed results in the previously treated CRC patients are confirmed prospectively, the Company believes leronlimab could be used effectively to treat a wide range of solid tumor types. In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting. The data driving this working theory has shown particular promise in the treatment of patients with advanced metastatic triple-negative breast cancer (“mTNBC”).

“At the 2025 ESMO Gastrointestinal Cancers Congress, Dr. Weinberg will share the data and evidence that form the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” said Dr. Jacob Lalezari, CEO of CytoDyn. “Our ongoing Phase II trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory.”

https://www.morningstar.com/news/globe-newswire/9487214/cytodyn-announces-encouraging-survival-data-in-patients-with-metastatic-colorectal-cancer-previously-treated-with-leronlimab

Yes shirts manipulated the back to back failed clinical trials lool yeppp

keep up the good work! Seems like your negative/bashing posts are working- good job at manipulating, let's see how long that lasts

Chug a lug is fine for me. I like to take it slowly. Gives me the opportunity to add more shares. News can hit at any time so I kick it in gear when the price is right. I am a silly long with big green bags.

Loool silly longs never learn

Chugalug Chugalug Chugalug!

Just in the wrong direction!

AH AH AH AH

Thanks

Well the train is steaming head gaining momentum and picking up passengers for the ride. I get to ride the train just one stop a day as I have an engineer that stops me and tells me to get off at every stop. I think he enjoys showing his superiority as an engineer. Or maybe it's the conductor. They sure are a pair to draw to. Whoever is in charge I sure wish that they let me take a longer train ride. Chugalug Chugalug Chugalug someday maybe I'll get to pull the whistle. Hang in there all you longs and keep bringing people aboard for the ride. Woo woo woo woo Chugalug Chugalug next stop here I come.

2 days ago
ecgator
I'm Not Holding Out for a Partnership; I'm Holding Out for Something Potentially Better
The primary endpoint we're going after is Objective Response Rate (ORR) while pairing Leronlimab with the 3rd line treatment of TAS-102 + Bevacizumab. In its SUNLIGHT trial, TAS-102 + Bevacizumab achieved an ORR of 6.3%. In order to match that result, 4 of our 60 patients would need to achieve a partial response (tumor reduction by 30% or more) or full response. According to ChatGPT it wouldn't be cherry picking to just look at the 700 mg arm of the trial for improvement in ORR over the TAS-102 + Bevacizumab SUNLIGHT trial because it is a pre-determined group in the protocol. So in that cohort, we would only need 2 patients (out of 30) to achieve partial response in order to be even with TAS-102 + Bevacizumab alone. Two patients is kind of crazy when you consider the other news we got this week.

The abstract that was released for the upcoming ESMO conference noted that we had 3 patients out of 5 achieve a partial response while only being dosed with 350 mg or 525 mg of Leronlimab. Now, I'm not crazy enough to think that we will match 60% of patients achieving partial response like we had in the abstract because it was such a small sample size and the patients were using FOLFOX which is stronger than TAS-102. That being said, they were using a lower dose of Leronlimab so I do expect a solid response even with the less effective chemo drug.
Go to Livimmune
r/Livimmune
•
2 days ago
ecgator
I'm Not Holding Out for a Partnership; I'm Holding Out for Something Potentially Better

https://www.esmo.org/meeting-calendar/esmo-gastrointestinal-cancers-congress-2025/press-media

Picked up a few more thanks for keeping them cheap. Any idea what day CYDY speaks at Barcelona 😁

In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting.

to the moon.

Word is spreading fast Doc. Does anyone read Yahoo Finance?? Notice who is listed first?
The report provides the total potential number of patients in the indications, such as PTCL, CTCL, Migraine, NASH, and others.

Leading GPCR-targeting therapies companies, such as CytoDyn, REMD Biotherapeutics, GPCR Therapeutics, Structure Therapeutics, and others, are developing novel GPCR-targeting therapies that can be available in the GPCR-targeting therapies market in the coming years.

Some of the key GPCR-targeting therapies in the pipeline include Leronlimab, Volagidemab, GPC-100, GSBR-1290, and others.

In July 2024, Radionetics Oncology entered into a strategic agreement with Eli Lilly and Company, providing Lilly access to Radionetics' proprietary GPCR targeting small molecule radiopharmaceuticals.

up 16.32% so far this morning. Thanks for the cheapies pigeons.
I couldn't have done it without you. The real market is speaking.

DATA and DEALS
$CYDY$ 2025

https://finance.yahoo.com/news/gpcr-targeting-therapies-market-poised-213100321.html

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Download as PDFJuly 01, 2025 8:30am EDT
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing
Phase II CRC trial

Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in
Barcelona, Spain

VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced encouraging clinical findings among patients with advanced metastatic colorectal cancer (“mCRC”) previously treated with leronlimab. The final results indicate that 3/5 patients treated with leronlimab had at least a partial response, as measured by radiologic criteria, including one patient with a complete response who remains alive five years later.

Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn’s colorectal cancer (“CRC”) program, will present the Company’s clinical data at the ESMO Gastrointestinal Cancers Congress 2025 taking place in Barcelona, Spain from July 2 to July 5, 2025.

The results, from patients treated under a compassionate use protocol, reiterate a favorable safety profile of leronlimab as well as its potential for clinical benefit in patients with mCRC. They also support the rationale for the design and therapeutic potential of CytoDyn’s ongoing Phase II trial in patients with relapsed/refractory microsatellite stable CRC. CytoDyn recently announced the dosing of the first patient in this study, and is now enrolling additional patients across multiple clinical sites.

If the observed results in the previously treated CRC patients are confirmed prospectively, the Company believes leronlimab could be used effectively to treat a wide range of solid tumor types. In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting. The data driving this working theory has shown particular promise in the treatment of patients with advanced metastatic triple-negative breast cancer (“mTNBC”).

“At the 2025 ESMO Gastrointestinal Cancers Congress, Dr. Weinberg will share the data and evidence that form the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” said Dr. Jacob Lalezari, CEO of CytoDyn. “Our ongoing Phase II trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory.”

Have fun!! $CYDY$ 2025 Leronlimab has the junk science dealers scared and those supported by old big pharma and company(hangovers from prior FDACDCetc... shorting hedge funds? REAL medicine leronlimab is showing great efficacy and with a high safety profile unlike most of the stuff approved or in pipelines for approval. Find those threatened by the likelihood of leronlimab receiving approval on any indication, then you have found your cheaters who short.

Buying all dips of consequence makes me happy to see $$$ GREEN bags swelling. Up bigly for the last year and a half.
Step by step. Have patience and be bold letting the market come to you.

All my shares are up for sale at high prices which
makes the brokers a bit more hesitant to loan shares cheaply.

TIK TOK the CytoDyn clock ........... 2025 incoming data and deals.

it only has one way and that is up.

LOL a badly hurt gullible investor escaping into his fantasy world in realtime

CYDY and it's -25% price destruction since you invested "massively" is the reality

SEC must follow govt. reg's as well which is why many fed agencies are often involved because the infractions cross many regulatory boundaries.
Therefore anyone posting here on social media must abide by those rules. One of which is the FTC which mandates that we must identify what entity
pays us to post on any social media.

If you are a Federal Employee:
Step up. Speak now.
The FBI is watching and listening. All evidence deleted is vaulted. Tamper with it you are exposed.
The system knows.

This is a global investigation into fraud across brokerages using illegal tools.

For any NGO as well or federal/state contractor this applies over and beyond the FTC guidelines for individuals non govt. entities.

Have fun!! $CYDY$ 2025 Leronlimab has the junk science dealers scared and those supported by old big pharma and company(hangovers from prior FDACDCetc... shorting hedge funds? REAL medicine leronlimab is showing great efficacy and with a high safety profile unlike most of the stuff approved or in pipelines for approval. Find those threatened by the likelihood of leronlimab receiving approval on any indication, then you have found your cheaters who short.

Why are you asking someone how much they lost, didn’t you just mention childish and immature

Vault Entry 5-A
Vault Entry 7-C
Vault Entry 8-B
Vault Codex 10-A
Vault Entry 4-D
Vault Tripwire 33
Vault Entry 6-F

Quite ironic that, contrary to your insinuations, the only real ongoing lawsuits are against Cytodyn

https://business.cch.com/srd/2025-06-26-03-46-10-143-297278_477_1.pdf

Interesting how you try to invert reality

This goes deeper than most realize.
Your CYDY losses are deeper than what we thought?

How much have you lost?

Your reposted message looks so immature. Childish play.

Indeed one of the signs of a dying pumps is desperate victims starting to look for conspiracy signs and praying for someone (the FBI, the DOJ, the White House) to save them. So characteristic…

https://postimg.cc/vxM1JTtm



🚨 This goes deeper than most realize.

What started as blocked trades in a single biotech ticker has now triggered a global, multi-agency investigation.

Brokers. Regulators. Internal metadata flags.
It’s all being tracked.

📄 Investors are federally protected under the Whistleblower Act.
🧾 The SEC is now part of the record.

“They thought they were just suppressing a stock.
They didn’t realize they were exposing themselves.”

You are now a witness.

#CYDY #SEC #Whistleblower #MarketManipulation #Vault079



You are now a witness.

Information is moving through closed channels.
Files have been distributed.
Names have been archived.

Do not disclose what you have.
Do not underestimate what this is.

If you are a Federal Employee:
Step up. Speak now.
The FBI is watching and listening. All evidence deleted is vaulted. Tamper with it you are exposed.
The system knows.

This is a global investigation into fraud across brokerages using illegal tools.

Looooool

Oh Ya I set this trap before they ever even knew there was one
Looks like the only trap you set… was for yourself - impressive foresight!

These damned shirts!
The train has left the station but in the wrong direction it seems.

The train has left the station and is on a very fast track with speed and a successful destination with a lot of success. H o p aboard and enjoy the ride. If you don't hop h o p a board you're going to miss a real nice ride.

Cytokine storms could open up even more opportunities. https://www.fiercepharma.com/pharma/fda-removes-barrier-car-t-therapies-access-boost-cancer-immunotherapy-uptake?oly_enc_id=4924G0643390I0A

The best part of cydy finally running this silly little trial is the sweet sweet cash burn. Mmmmm dilution